23 Jul, 2026
According to Straits Research, the global biopharmaceutical excipients market size was valued at $2.66 billion in 2025 and is projected to grow from $2.87 billion in 2026 to $5.22 billion by 2034 at a CAGR of 7.76% during the forecast period 2026-2034.
Biopharmaceutical excipients used in the pharmaceutical business are usually inert substances needed to ensure the medicine is safe, effective, and of good quality. These are chemicals other than functional medicine incorporated in the manufacturing process or the final dosage form of a pharmaceutical. Biopharmaceutical excipients are frequently added to formulations and dosage forms to stabilize proteins and maximize other desirable qualities. In addition to safety, toxicity, and immunogenicity, the knowledge of degradation pathways of active pharmaceutical ingredients and the methods by which different excipients mitigate those instabilities must influence the selection of pharmaceutical excipients.
Both large and small biopharmaceutical businesses are still searching for the molecular origins of cancer and developing anti-cancer medications. Thus, the biopharmaceutical business is at the forefront of shaping numerous elements of the oncology market. In low- and middle-income countries, infectious diseases such as HIV/AIDS, tuberculosis, and malaria contribute to a high death rate. In impoverished nations, contagious diseases are frequent due to a lack of understanding of personal hygiene, low healthcare expenditures, and ineffective physician services. The increased prevalence of infectious diseases in emerging nations creates the potential for biopharmaceuticals. Typically, drugs are required to treat these disorders. Excipients used in producing these biopharmaceutical medications are vital, and their demand is rising as the need for these drugs increases.
Novel excipients ensure that biopharmaceutical market medications are novel, improved, and safe. Some sophisticated products can only be formulated using innovative excipients because most approved products only comprise conventional, well-studied compendial excipients. More corporations choose to bring unique formulations with novel excipients. To modernize medication formulation and biopharmaceutical development processes, the FDA launched a testing program to evaluate the safety and acceptability of novel inactive components used in new pharmaceuticals and biologics. The purpose of this initiative is to encourage sponsors of clinical trials to develop innovative medicines using those new excipients deemed suitable for use by the FDA. An independent approval program will encourage biopharmaceutical companies to test innovative excipients and provide excipient providers with a route to market that does not need 15–20 years of waiting, stimulating market growth.
North America is the most significant shareholder in the global biopharmaceutical excipients market and is anticipated to grow at a CAGR of 7.15% during the forecast period. As infectious diseases become more prevalent, there is an increase in demand for biopharmaceutical excipients across the region. This expanding population necessitates massive quantities of drug development, a rise in the use of biologics, the emergence of novel and multifunctional excipients, an increase in vaccine awareness in developing nations, and the presence of a significant number of biopharmaceutical excipient manufacturers. Due to the frequency of infectious diseases in the North American region, the demand for biopharmaceutical medications such as vaccines, monoclonal antibodies, biologics, and others has increased.
Europe is anticipated to expand at a CAGR of 7.49% over the forecast period. Significant factors contributing to the growth of biopharmaceutical excipients in Europe include the growing elderly population, the prevalence of bacterial and viral infections, the rising demand for biologics, the increasing activity of multifunctional excipients, and the expansion of the biopharmaceutical and biotechnology industries. In addition, Europe is experiencing a rapid increase in the biotechnology and pharmaceutical industries. Due to its overall sizeable commercial potential, robust hotspots of research and industry expertise to support innovation, focus on advanced therapy medicinal products, and Europeans being more receptive to innovative drugs than US patients, it is likely to become the second-leading biotech sector after the United States. Europe is an important market for biotech businesses developing new pharmaceuticals, accounting for more than 20% of the worldwide pharmaceuticals market.
sales@straitsresearch.com